within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AA12_Tobramycin;

model Tobramycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.833333333333334e-07,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.00025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00011,
    k12 = 9.722222222222222e-07,
    k21 = 9.722222222222222e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tobramycin</td></tr><tr><td>ATC code:</td><td>S01AA12</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tobramycin is an aminoglycoside antibiotic primarily used to treat serious bacterial infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. It is commonly used in ophthalmic formulations and is approved for both systemic and topical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Praet, A, et al., &amp; Goutelle, S (2021). Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis. <i>Antimicrobial agents and chemotherapy</i> 65(10) e0073721–None. DOI:<a href=\"https://doi.org/10.1128/AAC.00737-21\">10.1128/AAC.00737-21</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34280011/\">https://pubmed.ncbi.nlm.nih.gov/34280011</a></p></li><li><p>Bloomfield, C, et al., &amp; Hennig, S (2016). Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. <i>Antimicrobial agents and chemotherapy</i> 60(6) 3407–3414. DOI:<a href=\"https://doi.org/10.1128/AAC.02654-15\">10.1128/AAC.02654-15</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27001806/\">https://pubmed.ncbi.nlm.nih.gov/27001806</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AA12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tobramycin;
